Rivaroxaban shows promise in ACS secondary prevention in ATLAS
This article was originally published in Scrip
Johnson & Johnson Pharmaceutical Research and Developmentand Bayerare to start a 16,000-patient Phase III study next month of their novel Factor Xa inhibitor rivaroxaban (Xarelto) in the potentially lucrative chronic use indication of ACS prevention based on encouraging Phase II data presented this week at the American Heart Association (AHA) meeting in New Orleans.
You may also be interested in...
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.